Vitamin D and colorectal cancer: Molecular, epidemiological and clinical evidence

British Journal of Nutrition

Volumn 115, Issue 9, 2016, Pages 1643-1660

  Dou, Ruoxu ^a,b   Ng, Kimmie ^a   Giovannucci, Edward L ^c,d   Manson, Joann E ^c,e   Qian, Zhi Rong ^a   Ogino, Shuji ^a,c,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

25 Hydroxyvitamin D: P450 hydroxylases: Vitamin D supplementation

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; COLECALCIFEROL 24 HYDROXYLASE; MICRORNA; OXYGENASE; PROTEIN CYP27B1; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CYTOCHROME P450; TRANSCRIPTION FACTOR; VITAMIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG EFFICACY; GENETIC VARIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOMODULATION; MOLECULAR INTERACTION; MOUSE MODEL; NONHUMAN; NUTRITIONAL STATUS; TUMOR VASCULARIZATION; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; BLOOD; COLORECTAL TUMOR; METABOLISM;

COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; RECEPTORS, CALCITRIOL; TRANSCRIPTION FACTORS; VITAMIN D; VITAMINS;

EID: 84968854149     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114516000696     Document Type: Article

References (174)

1. Holick MF (2006) The role of Vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 4, 96-102.
2. Garland CF & Garland FC (1980) Do sunlight and Vitamin D reduce the likelihood of colon cancer Int J Epidemiol 9, 227-231.
3. Deeb KK, Trump DL & Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7, 684-700.
4. Feldman D, Krishnan AV, Swami S, et al. (2014) The role of Vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14, 342-357.
5. Ogino S, Chan AT, Fuchs CS, et al. (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60, 397-411.
6. Ogino S & Stampfer M (2010) Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J Natl Cancer Inst 102, 365-367.
7. Holick MF (2006) Resurrection of Vitamin D deficiency and rickets. J Clin Invest 116, 2062-2072.
8. Ponchon G & DeLuca HF (1969) The role of the liver in the metabolism of Vitamin D. J Clin Invest 48, 1273-1279.
9. Fraser DR & Kodicek E (1970) Unique biosynthesis by kidney of a biological active Vitamin D metabolite. Nature 228, 764-766.
10. Young MV, Schwartz GG, Wang L, et al. (2004) The prostate 25-hydroxyVitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by Vitamin D. Carcinogenesis 25, 967-971.
11. Pike JW & Meyer MB (2012) Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyVitamin D(3) action. Arch Biochem Biophys 523, 2-8.
12. Christakos S, Dhawan P, Verstuyf A, et al. (2016) Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 96, 365-408.
13. Carlberg C, Bendik I, Wyss A, et al. (1993) Two nuclear signalling pathways for Vitamin D. Nature 361, 657-660.
14. Tagami T, Lutz WH, Kumar R, et al. (1998) The interaction of the Vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 253, 358-363.
15. Murayama A, Kim MS, Yanagisawa J, et al. (2004) Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J 23, 1598-1608.
16. Kim MS, Fujiki R, Murayama A, et al. (2007) 1Alpha,25(OH) 2D3-induced transrepression by Vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol Endocrinol 21, 334-342.
17. Haussler MR, Whitfield GK, Kaneko I, et al. (2013) Molecular mechanisms of Vitamin D action. Calcif Tissue Int 92, 77-98.
18. Haussler MR, Jurutka PW, Mizwicki M, et al. (2011) Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)Vitamin D(3): genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 25, 543-559.
19. Norman AW, Mizwicki MT & Norman DP (2004) Steroidhormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3, 27-41.
20. Ordonez-Moran P, Larriba MJ, Palmer HG, et al. (2008) RhoA-ROCK and p38MAPK-MSK1 mediate Vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J Cell Biol 183, 697-710.
21. Hsu JY, Feldman D, McNeal JE, et al. (2001) Reduced 1alphahydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyVitamin D3-induced growth inhibition. Cancer Res 61, 2852-2856.
22. Swami S, Krishnan AV, Wang JY, et al. (2012) Dietary Vitamin D(3) and 1,25-dihydroxyVitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153, 2576-2587.
23. Zehnder D, Bland R, Williams MC, et al. (2001) Extrarenal expression of 25-hydroxyVitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86, 888-894.
24. Cross HS, Bises G, Lechner D, et al. (2005) The Vitamin D endocrine system of the gut-its possible role in colorectal cancer prevention. J Steroid Biochem Mol Biol 97, 121-128.
25. Bises G, Kallay E, Weiland T, et al. (2004) 25-HydroxyVitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 52, 985-989.
26. Tangpricha V, Flanagan JN, Whitlatch LW, et al. (2001) 25-HydroxyVitamin D-1 alpha-hydroxylase in normal and malignant colon tissue. Lancet 357, 1673-1674.
27. Cross HS, Bareis P, Hofer H, et al. (2001) 25-HydroxyVitamin D(3)-1alpha-hydroxylase and Vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 66, 287-292.
28. Bareis P, Bises G, Bischof MG, et al. (2001) 25-HydroxyVitamin D metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 285, 1012-1017.
29. Ogunkolade BW, Boucher BJ, Fairclough PD, et al. (2002) Expression of 25-hydroxyVitamin D-1-hydroxylase mRNA in individuals with colorectal cancer. Lancet 359, 1831-1832.
30. Bareis P, Kallay E, Bischof MG, et al. (2002) Clonal differences in expression of 25-hydroxyVitamin D(3)-1alphahydroxylase, of 25-hydroxyVitamin D(3)-24-hydroxylase, and of the Vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha, 25-dihydroxyVitamin D(3). Exp Cell Res 276, 320-327.
31. Holt PR, Arber N, Halmos B, et al. (2002) Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy Vitamin D. Cancer Epidemiol Biomarkers Prev 11, 113-119.
32. Wagner D, Dias AG, Schnabl K, et al. (2012) Determination of 1,25-dihydroxyVitamin D concentrations in human colon tissues and matched serum samples. Anticancer Res 32, 259-263.
33. Horvath HC, Lakatos P, Kosa JP, et al. (2010) The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 58, 277-285.
34. Anderson MG, Nakane M, Ruan X, et al. (2006) Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57, 234-240.
35. Kosa JP, Horvath P, Wolfling J, et al. (2013) CYP24A1 inhibition facilitates the anti-tumor effect of Vitamin D3 on colorectal cancer cells. World J Gastroenterol 19, 2621-2628.
36. Wang Y, Zhu J & DeLuca HF (2012) Where is the Vitamin D receptor Arch Biochem Biophys 523, 123-133.
37. Matusiak D, Murillo G, Carroll RE, et al. (2005) Expression of Vitamin D receptor and 25-hydroxyVitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 14, 2370-2376.
38. Palmer HG, Larriba MJ, Garcia JM, et al. (2004) The transcription factor SNAIL represses Vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 10, 917-919.
39. Larriba MJ, Bonilla F & Munoz A (2010) The transcription factors Snail1 and Snail2 repress Vitamin D receptor during colon cancer progression. J Steroid Biochem Mol Biol 121, 106-109.
40. Ramagopalan SV, Heger A, Berlanga AJ, et al. (2010) A ChIP-seq defined genome-wide map of Vitamin D receptor binding: associations with disease and evolution. Genome Res 20, 1352-1360.
41. Meyer MB, Goetsch PD & Pike JW (2012) VDR-RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol 26, 37-51.
42. Goeman F, De Nicola F, D'Onorio De Meo P, et al. (2014) VDR primary targets by genome-wide transcriptional profiling. J Steroid Biochem Mol Biol 143, 348-356.
43. Shabahang M, Buras RR, Davoodi F, et al. (1993) 1,25-DihydroxyVitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 53, 3712-3718.
44. Scaglione-Sewell BA, Bissonnette M, Skarosi S, et al. (2000) A Vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology 141, 3931-3939.
45. Gaschott T, Steinmeyer A, Steinhilber D, et al. (2002) ZK 156718, a low calcemic, antiproliferative, and prodifferentiating Vitamin D analog. Biochem Biophys Res Commun 290, 504-509.
46. Berkovich L, Sintov AC & Ben-Shabat S (2013) Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived Vitamin D3 analogs, in-vitro and in-vivo studies. Invest New Drugs 31, 247-255.
47. Chen AP, Davis BH, Sitrin MD, et al. (2002) Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D-3. Am J Physiol Gastrointest Liver Physiol 283, G864-G874.
48. Oh YS, Kim EJ, Schaffer BS, et al. (2001) Synthetic lowcalcaemic Vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 183, 141-149.
49. Tong WM, Hofer H, Ellinger A, et al. (1999) Mechanism of antimitogenic action of Vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. Oncol Res 11, 77-84.
50. Diaz GD, Paraskeva C, Thomas MG, et al. (2000) Apoptosis is induced by the active metabolite of Vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60, 2304-2312.
51. Chen A, Davis BH, Bissonnette M, et al. (1999) 1,25-DihydroxyVitamin D(3) stimulates activator protein-1-dependent Caco-2 cell differentiation. J Biol Chem 274, 35505-35513.
52. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. (2001) Vitamin D-3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154, 369-387.
53. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, et al. (2003) Genetic signatures of differentiation induced by 1alpha,25-dihydroxyVitamin D3 in human colon cancer cells. Cancer Res 63, 7799-7806.
54. Xu H, Posner GH, Stevenson M, et al. (2010) Apc(MIN) modulation of Vitamin D secosteroid growth control. Carcinogenesis 31, 1434-1441.
55. Egan JB, Thompson PA, Vitanov MV, et al. (2010) Vitamin D receptor ligands, adenomatous polyposis coli, and the Vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells. Mol Carcinog 49, 337-352.
56. Aguilera O, Pena C, Garcia JM, et al. (2007) The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha, 25-dihydroxyVitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28, 1877-1884.
57. Barnes JD, Arhel NJ, Lee SS, et al. (2005) Nuclear BAG-1 expression inhibits apoptosis in colorectal adenoma-derived epithelial cells. Apoptosis 10, 301-311.
58. Liu G, Hu X & Chakrabarty S (2010) Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer 126, 631-639.
59. Canaff L & Hendy GN (2002) Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyVitamin D. J Biol Chem 277, 30337-30350.
60. Chakrabarty S, Wang HM, Canaff L, et al. (2005) Calcium sensing receptor in human colon carcinoma: interaction with Ca2+ and 1,25-dihydroxyVitamin D-3. Cancer Res 65, 493-498.
61. Yang K, Lamprecht SA, Shinozaki H, et al. (2008) Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli1638N/ + mice. J Nutr 138, 1658-1663.
62. Stambolsky P, Tabach Y, Fontemaggi G, et al. (2010) Modulation of the Vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17, 273-285.
63. Mantell DJ, Owens PE, Bundred NJ, et al. (2000) 1 alpha, 25-DihydroxyVitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87, 214-220.
64. Ben-Shoshan M, Amir S, Dang DT, et al. (2007) 1 alpha, 25-DihydroxyVitamin D-3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 6, 1433-1439.
65. Fernandez-Garcia NI, Palmer HG, Garcia M, et al. (2005) 1 alpha, 25-DihydroxyVitamin D-3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 24, 6533-6544.
66. Pendas-Franco N, Garcia JM, Pena C, et al. (2008) DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxy Vitamin D3. Oncogene 27, 4467-4477.
67. Iseki K, Tatsuta M, Uehara H, et al. (1999) Inhibition of angiogenesis as a mechanism for inhibition by 1alphahydroxyVitamin D3 and 1,25-dihydroxyVitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81, 730-733.
68. van Harten-Gerritsen AS, Balvers MG, Witkamp RF, et al. (2015) Vitamin D, inflammation and colorectal cancer progression: a review of mechanistic studies and future directions for epidemiological studies. Cancer Epidemiol Biomarkers Prev 24, 1820-1828.
69. Gombart AF, Borregaard N & Koeffler HP (2005) Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the Vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyVitamin D-3. FASEB J 19, 1067-1077.
70. Sun J, Mustafi R, Cerda S, et al. (2008) Lithocholic acid down-regulation of NF-kappa B activity through Vitamin D receptor in colonic cancer cells. J Steroid Biochem Mol Biol 111, 37-40.
71. Liu N, Nguyen L, Chun RF, et al. (2008) Altered endocrine and autocrine metabolism of Vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 149, 4799-4808.
72. Meeker S, Seamons A, Paik J, et al. (2014) Increased dietary Vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res 74, 4398-4408.
73. Veldhoen M & Brucklacher-Waldert V (2012) Dietary influences on intestinal immunity. Nat Rev Immunol 12, 696-708.
74. Bruce D & Cantorna MT (2011) Intrinsic requirement for the Vitamin D receptor in the development of CD8alphaalphaexpressing T cells. J Immunol 186, 2819-2825.
75. van Wijk F & Cheroutre H (2009) Intestinal T cells: facing the mucosal immune dilemma with synergy and diversity. Semin Immunol 21, 130-138.
76. Wada K, Tanaka H, Maeda K, et al. (2009) Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 22, 1021-1025.
77. Hummel DM, Fetahu IS, Groschel C, et al. (2014) Role of proinflammatory cytokines on expression of Vitamin D metabolism and target genes in colon cancer cells. J Steroid Biochem Mol Biol 144, 91-95.
78. Johnson CH, Dejea CM, Edler D, et al. (2015) Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab 21, 891-897.
79. Mima K, Sukawa Y, Nishihara R, et al. (2015) Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 1, 653-661.
80. O'Keefe SJ, Li JV, Lahti L, et al. (2015) Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun 6, 6342.
81. Lagishetty V, Misharin AV, Liu NQ, et al. (2010) Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology 151, 2423-2432.
82. Ooi JH, Li Y, Rogers CJ, et al. (2013) Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr 143, 1679-1686.
83. Alvarez-Diaz S, Valle N, Ferrer-Mayorga G, et al. (2012) MicroRNA-22 is induced by Vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet 21, 2157-2165.
84. Padi SK, Zhang Q, Rustum YM, et al. (2013) MicroRNA-627 mediates the epigenetic mechanisms of Vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice. Gastroenterology 145, 437-446.
85. Newmark HL, Yang K, Kurihara N, et al. (2009) Westernstyle diet-induced colonic tumors and their modulation by calcium and Vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 30, 88-92.
86. Mokady E, Schwartz B, Shany S, et al. (2000) A protective role of dietary Vitamin D3 in rat colon carcinogenesis. Nutr Cancer 38, 65-73.
87. Hummel DM, Thiem U, Hobaus J, et al. (2013) Prevention of preneoplastic lesions by dietary Vitamin D in a mouse model of colorectal carcinogenesis. J Steroid Biochem Mol Biol 136, 284-288.
88. Tangpricha V, Spina C, Yao M, et al. (2005) Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 135, 2350-2354.
89. Milczarek M, Psurski M, Kutner A, et al. (2013) Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer 13, 294.
90. Milczarek M, Rosinska S, Psurski M, et al. (2013) Combined colonic cancer treatment with Vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res 33, 433-444.
91. Huerta S, Irwin RW, Heber D, et al. (2002) 1 alpha,25-(OH) (2)-D-3 and its synthetic analogue decrease tumor load in the Apc(min) mouse. Cancer Res 62, 741-746.
92. Kallay E, Pietschmann P, Toyokuni S, et al. (2001) Characterization of a Vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22, 1429-1435.
93. Jesus Larriba M, Ordonez-Moran P, Chicote I, et al. (2011). Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. PLoS ONE 6, e23524.
94. Bostick RM (2015) Effects of supplemental Vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms. J Steroid Biochem Mol Biol 148, 86-95.
95. Fedirko V, Bostick RM, Flanders WD, et al. (2009) Effects of Vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev Res 2, 213-223.
96. Fedirko V, Bostick RM, Flanders WD, et al. (2009) Effects of Vitamin D and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18, 2933-2941.
97. Ahearn TU, Shaukat A, Flanders WD, et al. (2012) A randomized clinical trial of the effects of supplemental calcium and Vitamin D3 on the APC/beta-catenin pathway in the normal mucosa of colorectal adenoma patients. Cancer Prev Res 5, 1247-1256.
98. Sidelnikov E, Bostick RM, Flanders WD, et al. (2010) Effects of calcium and Vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients. Cancer Epidemiol Biomarkers Prev 19, 1022-1032.
99. Ahearn TU, McCullough ML, Flanders WD, et al. (2011) A randomized clinical trial of the effects of supplemental calcium and Vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients. Cancer Res 71, 413-423.
100. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357, 266-281.
101. Ross AC, Manson JE, Abrams SA, et al. (2011) The 2011 report on dietary reference intakes for calcium and Vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96, 53-58.
102. Davis CD & Dwyer JT (2007) The 'sunshine Vitamin': benefits beyond bone J Natl Cancer Inst 99, 1563-1565.
103. Autier P, Boniol M, Pizot C, et al. (2014) Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2, 76-89.
104. Song M, Wu K, Chan AT, et al. (2014) Plasma 25-hydroxyVitamin D and risk of colorectal cancer after adjusting for inflammatory markers. Cancer Epidemiol Biomarkers Prev 23, 2175-2180.
105. Hofmann JN, Yu K, Horst RL, et al. (2010) Long-term variation in serum 25-hydroxyVitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 19, 927-931.
106. Grant WB (2011) Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyVitamin D level: implications for metaanalyses and setting Vitamin D guidelines. Dermatoendocrinol 3, 199-204.
107. Cheng TY, Millen AE, Wactawski-Wende J, et al. (2014) Vitamin D intake determines Vitamin D status of postmenopausal women, particularly those with limited sun exposure. J Nutr 144, 681-689.
108. Bertrand KA, Giovannucci E, Liu Y, et al. (2012) Determinants of plasma 25-hydroxyVitamin D and development of prediction models in three US cohorts. Br J Nutr 108, 1889-1896.
109. Jung S, Qian ZR, Yamauchi M, et al. (2014) Predicted 25(OH)D score and colorectal cancer risk according to Vitamin D receptor expression. Cancer Epidemiol Biomarkers Prev 23, 1628-1637.
110. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. (2006) Calcium plus Vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354, 684-696.
111. Wu K, Feskanich D, Fuchs CS, et al. (2007) A nested case-control study of plasma 25-hydroxyVitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 99, 1120-1129.
112. Otani T, Iwasaki M, Sasazuki S, et al. (2007) Plasma Vitamin D and risk of colorectal cancer: The Japan Public Health Center-Based Prospective Study. Br J Cancer 97, 446-451.
113. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. (2010) Association between pre-diagnostic circulating Vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 340, b5500.
114. Lee JE, Li H, Chan AT, et al. (2011) Circulating levels of Vitamin D and colon and rectal cancer: The Physicians' Health Study and a Meta-analysis of Prospective Studies. Cancer Prev Res 4, 735-743.
115. Ma Y, Zhang P, Wang F, et al. (2011) Association between Vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 29, 3775-3782.
116. Chung M, Lee J, Terasawa T, et al. (2011) Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Inter Med 155, 827-838.
117. Neuhouser ML, Manson JE, Millen A, et al. (2012) The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyVitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol 175, 673-684.
118. English DR, Williamson EJ, Heath AK, et al. (2013) Abstract A54: Vitamin D and risk of colorectal cancer: The Melbourne Collaborative Cohort Study. Cancer Prev Res 6, A54.
119. Anic GM, Weinstein SJ, Mondul AM, et al. (2014) Serum Vitamin D, Vitamin D binding protein, and risk of colorectal cancer. PLOS ONE 9, e102966.
120. Theodoratou E, Tzoulaki I, Zgaga L, et al. (2014) Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 348, g2035.
121. Weinstein SJ, Purdue MP, Smith-Warner SA, et al. (2015) Serum 25-hydroxyVitamin D, Vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 136, E654-E664.
122. Song M, Nishihara R, Wang M, et al. (2015) Plasma 25-hydroxyVitamin D and colorectal cancer risk according to tumour immunity status. Gut 65, 269-304.
123. Lee JE (2011) Circulating levels of Vitamin D, Vitamin D receptor polymorphisms, and colorectal adenoma: a meta-analysis. Nutr Res Pract 5, 464-470.
124. Yin L, Grandi N, Raum E, et al. (2011) Meta-analysis: serum Vitamin D and colorectal adenoma risk. Preven Med 53, 10-16.
125. Ogino S, Lochhead P, Chan AT, et al. (2013) Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 26, 465-484.
126. Ogino S, Campbell PT, Nishihara R, et al. (2015) Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 26, 959-972.
127. Wang M, Kuchiba A & Ogino S (2015) A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol 182, 263-270.
128. Wang M, Spiegelman D, Kuchiba A, et al. (2015) Statistical methods for studying disease subtype heterogeneity. Stat Med 35, 782-800.
129. Edfeldt K, Liu PT, Chun R, et al. (2010) T-cell cytokines differentially control human monocyte antimicrobial responses by regulating Vitamin D metabolism. Proc Natl Acad Sci U S A 107, 22593-22598.
130. Liu PT, Stenger S, Li H, et al. (2006) Toll-like receptor triggering of a Vitamin D-mediated human antimicrobial response. Science 311, 1770-1773.
131. Sigmundsdottir H, Pan J, Debes GF, et al. (2007) DCs metabolize sunlight-induced Vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 8, 285-293.
132. Nishihara R, VanderWeele TJ, Shibuya K, et al. (2015) Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol 30, 1129-1135.
133. Ng K, Meyerhardt JA, Wu K, et al. (2008) Circulating 25-hydroxyVitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 26, 2984-2991.
134. Ng K, Wolpin BM, Meyerhardt JA, et al. (2009) Prospective study of predictors of Vitamin D status and survival in patients with colorectal cancer. Br J Cancer 101, 916-923.
135. Ng K, Sargent DJ, Goldberg RM, et al. (2011) Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol 29, 1599-1606.
136. Fedirko V, Riboli E, Tjonneland A, et al. (2012) Prediagnostic 25-hydroxyVitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomarkers Prev 21, 582-593.
137. Zgaga L, Theodoratou E, Farrington SM, et al. (2014) Plasma Vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol 32, 2430-2439.
138. Maalmi H, Ordonez-Mena JM, Schottker B, et al. (2014) Serum 25-hydroxyVitamin D levels and survival in colorectal and breast cancer patients: systematic review and metaanalysis of prospective cohort studies. Eur J Cancer 50, 1510-1521.
139. Ng K, Venook AP, Sato K, et al. (2015) Vitamin D status and survival of metastatic colorectal cancer patients: results from CALGB/SWOG 80405 (alliance). J Clin Oncol 33, Suppl. 3, 507.
140. Martinez ME, Giovannucci EL, Colditz GA, et al. (1996) Calcium, Vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst 88, 1375-1382.
141. Pritchard RS, Baron JA & deVerdier MG (1996) Dietary calcium, Vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers Prev 5, 897-900.
142. Terry P, Baron JA, Bergkvist L, et al. (2002) Dietary calcium and Vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. Nutr Cancer 43, 39-46.
143. Slattery ML, Neuhausen SL, Hoffman M, et al. (2004) Dietary calcium, Vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 111, 750-756.
144. Park SY, Murphy SP, Wilkens LR, et al. (2007) Calcium and Vitamin D intake and risk of colorectal cancer: The Multiethnic Cohort Study. Am J Epidemiol 165, 784-793.
145. Mizoue T, Kimura Y, Toyomura K, et al. (2008) Calcium, dairy foods, Vitamin D, and colorectal cancer risk: The Fukuoka Colorectal Cancer Study. Cancer Epidemiol Biomarkers Prev 17, 2800-2807.
146. Ishihara J, Inoue M, Iwasaki M, et al. (2008) Dietary calcium, Vitamin D, and the risk of colorectal cancer. Am J Clin Nutr 88, 1576-1583.
147. Lipworth L, Bender TJ, Rossi M, et al. (2009) Dietary Vitamin D intake and cancers of the colon and rectum: a case-control study in Italy. Nutr Cancer 61, 70-75.
148. Huncharek M, Muscat J & Kupelnick B (2009) Colorectal cancer risk and dietary intake of calcium, Vitamin D, and dairy products: a meta-analysis of 26335 cases from 60 observational studies. Nutr Cancer 61, 47-69.
149. Marcus PM & Newcomb PA (1998) The association of calcium and Vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 27, 788-793.
150. McCullough ML, Robertson AS, Rodriguez C, et al. (2003) Calcium, Vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 14, 1-12.
151. Yang B, McCullough ML, Gapstur SM, et al. (2014) Calcium, Vitamin D, dairy products, and mortality among colorectal cancer survivors: The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 32, 2335-2343.
152. Trivedi DP, Doll R & Khaw KT (2003) Effect of four monthly oral Vitamin D-3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326, 469-472.
153. Lappe JM, Travers-Gustafson D, Davies KM, et al. (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85, 1586-1591.
154. Avenell A, MacLennan GS, Jenkinson DJ, et al. (2012) Longterm follow-up for mortality and cancer in a randomized placebo-controlled trial of Vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 97, 614-622.
155. Ng K, Scott JB, Drake BF, et al. (2014) Dose response to Vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. Am J Clin Nutr 99, 587-598.
156. Bolland MJ, Grey A, Gamble GD, et al. (2011) Calcium and Vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr 94, 1144-1149.
157. Baron JA, Barry EL, Mott LA, et al. (2015) A trial of calcium and Vitamin D for the prevention of colorectal adenomas. N Engl J Med 373, 1519-1530.
158. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. (2006) Estimation of optimal serum concentrations of 25-hydroxyVitamin D for multiple health outcomes. Am J Clin Nutr 84, 18-28.
159. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, et al. (2010) Benefit-risk assessment of Vitamin D supplementation. Osteoporos Int 21, 1121-1132.
160. Giovannucci E (2013) Epidemiology of Vitamin D and colorectal cancer. Anticancer Agents Med Chem 13, 11-19.
161. Kunzmann AT, Coleman HG, Huang WY, et al. (2015)Dietary fiber intake and risk of colorectal cancer and incident and recurrent adenoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr 102, 881-890.
162. Manson JE & Bassuk SS (2015) Vitamin D research and clinical practice: at a crossroads. JAMA 313, 1311-1312.
163. Pradhan AD & Manson JE (2015) Update on the Vitamin D and OmegA-3 trial (VITAL). J Steroid Biochem Mol Biol 155, 252-256.
164. Lichtenstein P, Holm NV, Verkasalo PK, et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343, 78-85.
165. Shea M, Benjamin E, Dupuis J, et al. (2009) Genetic and non-genetic correlates of Vitamins K and D. Eur J Clin Nutr 63, 458-464.
166. Wang TJ, Zhang F, Richards JB, et al. (2010) Common genetic determinants of Vitamin D insufficiency: a genome-wide association study. Lancet 376, 180-188.
167. Hiraki LT, Qu C, Hutter CM, et al. (2013) Genetic predictors of circulating 25-hydroxyVitamin D and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 22, 2037-2046.
168. Jorde R, Schirmer H, Wilsgaard T, et al. (2012) Polymorphisms related to the serum 25-hydroxyVitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromso Study. PLOS ONE 7, e37295.
169. Peters U, Bien S & Zubair N (2015) Genetic architecture of colorectal cancer. Gut 64, 1623-1636.
170. Koestner K, Denzer N, Mueller CSL, et al. (2009) The relevance of Vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 29, 3511-3536.
171. Touvier M, Chan DSM, Lau R, et al. (2011) Meta-analyses of Vitamin D intake, 25-hydroxyVitamin D status, Vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 20, 1003-1016.
172. Serrano D, Gnagnarella P, Raimondi S, et al. (2015) Metaanalysis on Vitamin D receptor and cancer risk: focus on the role of TaqI, ApaI, and Cdx2 polymorphisms. Eur J Cancer Prev 25, 85-96.
173. Hiraki LT, Joshi AD, Ng K, et al. (2014) Joint effects of colorectal cancer susceptibility loci, circulating 25-hydroxyVitamin D and risk of colorectal cancer. PLOS ONE 9, e92212.
174. Ferguson LR, Laing B, Marlow G, et al. (2015) The role of Vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs: focus on genetic and genomic technologies. Mol Nutr Food Res 60, 119-133.